What is diabetes explain types and cure in details

Reading File

Finding Sources

Reading File

I now have comprehensive information to provide a detailed answer. Let me compile everything.

Diabetes Mellitus — A Comprehensive Overview

What Is Diabetes?

Diabetes mellitus is a syndrome of impaired carbohydrate, fat, and protein metabolism caused by either lack of insulin secretion or decreased sensitivity of tissues to insulin. It is defined as an elevated blood glucose associated with absent or inadequate pancreatic insulin secretion, with or without concurrent impairment of insulin action.

The result: cells cannot efficiently uptake and use glucose → blood glucose rises → tissues shift to burning fat and protein → multiple systemic complications.

The Four Types of Diabetes

1. Type 1 Diabetes Mellitus (T1DM)

Mechanism: The hallmark of type 1 diabetes is selective beta cell destruction leading to severe or absolute insulin deficiency. It is subdivided into:

Type 1a — immune-mediated (most common): Autoantibodies destroy beta cells. Key autoantibodies include:
- Islet cell antibodies (ICAs)
- Insulin autoantibodies (IAAs)
- Anti-glutamic acid decarboxylase (GAD-65)
- Anti-tyrosine phosphatase IA-2 (ICA 512)
- Anti-zinc transporter 8 (ZnT8)
Type 1b — idiopathic (no autoimmune markers)

Key features:

Accounts for ~5–10% of all diabetes
Often presents in children and adolescents (formerly "juvenile diabetes"), but can occur at any age
Strong genetic association with HLA-DR and HLA-DQ loci
Prone to diabetic ketoacidosis (DKA) — fat metabolism accelerates, producing keto acids (acetoacetic acid, β-hydroxybutyric acid), leading to metabolic acidosis
Insulin therapy is essential from the start

New development: Teplizumab-mzwv, a humanized anti-CD3 monoclonal antibody, is now FDA-approved for high-risk individuals (stage 2 T1DM). A 14-day infusion course delays onset of clinical diabetes by approximately 25 months.

2. Type 2 Diabetes Mellitus (T2DM)

Mechanism: A heterogeneous condition with two core defects:

Insulin resistance — target tissues (muscle, liver, adipose) become resistant to insulin's actions
Progressive beta cell failure — the pancreas initially compensates with more insulin output, but beta cells gradually decline

Key features:

Most common form of diabetes (~90–95% of cases)
Typically presents in adulthood (though increasingly seen in younger people)
Less prone to DKA (circulating insulin is enough to suppress ketogenesis)
Initially manageable with diet, exercise, and oral medications
May eventually require insulin as beta cell function declines
LADA (Latent Autoimmune Diabetes of Adulthood) — up to 10–15% of patients diagnosed as "type 2" actually have a slow autoimmune form resembling T1DM

3. Gestational Diabetes Mellitus (GDM)

Mechanism: Any abnormality in glucose levels first noted during pregnancy. The placenta and placental hormones create pronounced insulin resistance, especially in the third trimester.

Key features:

Affects ~7% of all pregnancies in the US
Insulin is the drug of choice for management during pregnancy (metformin is generally well tolerated as an alternative)
Resolves after delivery in most cases, but increases lifetime risk of T2DM

4. Other Specific Types

Secondary diabetes due to:

Exocrine pancreatic disease — pancreatitis, pancreatectomy, cystic fibrosis
Other endocrinopathies — Cushing syndrome, acromegaly, pheochromocytoma
Drugs/toxins — corticosteroids, thiazide diuretics, atypical antipsychotics
Genetic defects affecting beta cells — MODY (Maturity Onset Diabetes of the Young): multiple genetic subtypes
Genetic defects in insulin receptors — cause severe insulin resistance, sometimes associated with acanthosis nigricans

Pathophysiology: What Happens in the Body

Effect	Mechanism
Hyperglycemia	Decreased glucose uptake + increased hepatic glucose output → plasma glucose 300–1200 mg/dL
Glucosuria	Blood glucose exceeds renal threshold (~200 mg/dL) → glucose spills into urine
Polyuria & dehydration	Osmotic diuresis from glucosuria → massive fluid loss
Polydipsia	Dehydration triggers thirst
DKA (T1DM)	Absent insulin → fat catabolism → keto acid accumulation → metabolic acidosis
Chronic tissue injury	Vascular and neural damage from sustained hyperglycemia

Chronic complications of uncontrolled diabetes include: heart attack, stroke, end-stage kidney disease, retinopathy/blindness, peripheral neuropathy, and limb ischemia/gangrene.

Diagnosis

Test	Pre-diabetes	Diabetes
Fasting plasma glucose	100–125 mg/dL	≥ 126 mg/dL
2-hr OGTT (75g glucose)	140–199 mg/dL	≥ 200 mg/dL
HbA1c	5.7–6.4%	≥ 6.5%
Random glucose (with symptoms)	—	≥ 200 mg/dL

HbA1c reflects average blood glucose over the preceding 8–12 weeks (red cell lifespan). A cutoff of ≥6.5% was chosen because retinopathy risk rises sharply above this value.

Treatment & Management

Type 1 Diabetes — Treatment

Insulin is mandatory. Without it, DKA and death occur. Types of insulin regimens range from multiple daily injections (basal-bolus) to continuous subcutaneous insulin infusion (insulin pumps).

Novel disease-modifying therapy:

Teplizumab (Tzield) — Anti-CD3 antibody that modulates the autoimmune T-cell response. Approved to delay onset of clinical T1DM in high-risk individuals (positive autoantibodies + impaired glucose tolerance, age ≥8 years). Not a cure, but delays disease progression by ~2 years.

Type 2 Diabetes — Treatment (Stepwise)

1. Lifestyle modification (first-line always):

Dietary changes (low glycemic index foods, caloric restriction)
Regular aerobic exercise (improves insulin sensitivity)
Weight loss (even 5–10% body weight significantly improves glycemia)

2. Oral and injectable medications:

Drug Class	Mechanism	Examples
Biguanides	Decrease hepatic glucose production	Metformin (first-line drug)
Sulfonylureas	Stimulate insulin release from beta cells (close K⁺-ATP channels → depolarization → Ca²⁺ influx → insulin secretion)	Glipizide, glyburide, glimepiride
GLP-1 receptor agonists	Enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying	Semaglutide (Ozempic), liraglutide
SGLT2 inhibitors	Block renal glucose reabsorption → glucosuria	Empagliflozin, dapagliflozin
DPP-4 inhibitors	Prevent GLP-1 breakdown → prolong incretin effect	Sitagliptin, saxagliptin
Thiazolidinediones	Improve insulin sensitivity (PPAR-γ agonists)	Pioglitazone
Meglitinides	Short-acting insulin secretagogues	Repaglinide, nateglinide

3. Insulin therapy — added when oral agents fail to maintain target HbA1c, or during acute illness/surgery.

Is There a Cure?

Type	Cure Status
Type 1	No definitive cure currently. Teplizumab delays onset but does not prevent or reverse it. Pancreatic islet transplantation can temporarily restore insulin independence but requires immunosuppression. Research on beta cell regeneration and encapsulation is ongoing.
Type 2	Potentially reversible with aggressive lifestyle intervention or bariatric surgery (particularly gastric bypass), which can achieve sustained remission in many patients — especially if caught early and significant weight loss is achieved. However, it recurs if lifestyle changes are not maintained.
Gestational	Resolves after delivery in most cases.

Key takeaway: Type 2 diabetes — unlike Type 1 — is largely a disease of lifestyle and metabolism, making it uniquely amenable to prevention and even remission. Type 1 remains an autoimmune disease requiring lifelong insulin replacement, with emerging therapies aimed at slowing its progression.

Sources: Katzung's Basic and Clinical Pharmacology 16e | Guyton and Hall Textbook of Medical Physiology | Quick Compendium of Clinical Pathology 5e | Textbook of Family Medicine 9e

This is a shared conversation. Sign in to Orris to start your own chat.